TickerTalks
Browse all tickers →
TickerTalks›$CABA
CACABA

Cabaletta Bio, Inc.

$CABA·$239M·Biotechnology·Healthcare
$1.48+5.0%YTD-30.5%1Y-51.0%
Price updated 9h ago·X counts updated 8d ago
CACABA
$CABACabaletta Bio, Inc.
$1.48+4.96%64 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $CABA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

64X posts · last 7 days
Oct 2Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $CABA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-08

Cabaletta Bio has a 17-patient IIM pivotal underway with BLA filing in H2 2027 and starts a second 25-patient SSc pivotal in Q4 2026. Expected >80% gross margins on ~$750K average price. 28% short interest with strong volume and close.

Read what X is saying about $CABA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CABA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Cabaletta Bio is near 52-week lows with a 17-patient IIM pivotal running — BLA H2 2027 and 28% short interest.

Cabaletta Bio is developing CAR-T therapies for autoimmune disease — not oncology. The IIM (idiopathic inflammatory myopathy) and SSc (systemic sclerosis) pivotals are the actual thesis.

  • The business is pre-revenue: PS 0, PE -2.3, ROIC -79% — standard clinical-stage biotech P&L where the thesis is pivotal readouts and strategic optionality.
  • The pipeline signal is specific: 17-patient IIM pivotal underway with BLA filing in H2 2027, 25-patient SSc pivotal starting Q4 2026, >80% expected gross margins on ~$750K average price per dose — concrete trial design plus commercial math.
  • 52-week range position is 1.3% at $1.89 with vol multiplier 1.48 — near-absolute capitulation on above-average volume, with 28% short interest and strong-close volume adding a squeeze overlay.

Nov 9 Q3 is the gate — any additional IIM enrollment milestone plus SSc trial-start confirmation extends the stock off the floor. A dilutive raise or any safety signal and the stock stays at the lows.

Agrees with X sentimentThe thread has substantive drivers — specific 17-patient IIM pivotal, BLA H2 2027 filing, 25-patient SSc pivotal starting Q4 2026, >80% gross margins on $750K average price, 28% short interest with strong volume — all grounded.

What to watch: Nov 9 Q3 — IIM enrollment update, SSc trial start, operating cash runway, and any safety-signal commentary. A dilutive raise is the hard invalidator.

On the calendar: 2026-11-09 — Q3 earnings

Read the AI verdict on $CABA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing engineered CAR-T and antibody-based therapies aimed at eliminating autoreactive B cells driving lupus and pemphigus.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CABA.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $CABA

Neutral — Clinical-stage biotech developing engineered CAR-T and antibody-based therapies aimed at eliminating autoreactive B cells driving lupus and pemphigus.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-78.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-26.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-128%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.34$-0.37+8.8%
Q1 2026May 14, 2026$-0.39$-0.41+4.9%
Q4 2025Mar 23, 2026$-0.40$-0.45+11.1%
Q3 2025Nov 10, 2025$-0.44$-0.49+10.2%
Next earningsMon, Nov 9·consensus EPS $-0.33

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.34$-41.5M
Q1 FY26$0———$-0.39$-42.6M
Q4 FY25$0———$-0.41$-35.5M
Q3 FY25$0———$-0.44$-34.6M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.5M$2.5M – $2.5M-$1.36-$1.46 – -$1.176
FY27$713K$713K – $713K-$1.20-$1.37 – -$1.087
FY28$63.7M$63.7M – $63.7M-$0.99-$1.40 – -$0.518
FY29$354.5M$354.5M – $354.5M-$0.47-$0.47 – -$0.476
FY30$790.2M$790.2M – $790.2M$0.82$0.82 – $0.826

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-42.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-48.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 141.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β3.485-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 5 other (5 awards) in window

See when $CABA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KCharter amendmentJun 118-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
8-KPress release / Reg FDJun 38-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KPress release / Reg FDMay 148-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KMaterial agreementMay 48-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 8.01: Other event
424B5Prospectus supplement (offering)May 4424B5
+ 21 other (11 13Gs · 3 proxys · 2 routine 8-Ks · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concernsseekingalpha.com·7d agoCabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·15d agoCabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·36d agoCabaletta Bio to Participate in Upcoming Investor Conferencesglobenewswire.com·49d agoCabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com·68d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $CABA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport